• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在间变性甲状腺癌患者中,治疗方法和生存率因种族/民族而异。

Treatment and survival vary by race/ethnicity in patients with anaplastic thyroid cancer.

机构信息

Division of Otolaryngology-Head and Neck Surgery, Hofstra Northwell School of Medicine, Staten Island, New York.

Surveillance and Health Services Research, American Cancer Society, Atlanta, Georgia.

出版信息

Cancer. 2018 Apr 15;124(8):1780-1790. doi: 10.1002/cncr.31252. Epub 2018 Feb 6.

DOI:10.1002/cncr.31252
PMID:29409119
Abstract

BACKGROUND

Anaplastic thyroid cancer (ATC) is the rarest type of thyroid cancer and has the lowest overall survival. To the authors' knowledge, the impact of socioeconomic status and race/ethnicity has not yet been described.

METHODS

Data regarding 719 patients diagnosed with their first primary malignant ATC from January 1, 1998 to December 31, 2011 in the Surveillance, Epidemiology, and End Results program registries were examined. Differences in receipt of thyroidectomy, radiotherapy, and lymph node examination were examined by race/ethnicity. Survival also was examined by race/ethnicity.

RESULTS

Nearly 70% of patients were non-Hispanic white, and 55.4% of patients received treatment. Tumor size (P = .13), lymph node involvement (P = .60), and residence in high poverty neighborhoods (P = .08) did not vary by race/ethnicity. Nonwhite patients were more likely to receive no treatment (adjusted odds ratio, 0.29; 95% confidence interval [95% CI], 0.16-0.54). When receipt of radiotherapy was adjusted for, nonwhite patients had a higher risk of overall death (adjusted hazards ratio [aHR], 1.24; 95% CI, 1.01-1.54), although not disease-specific death (aHR, 1.14; 95% CI, 0.92-1.42). Patients living in areas of high poverty had lower overall survival (aHR, 1.54; 95% CI, 1.09-2.18) and disease-specific survival (aHR, 1.68; 95% CI, 1.19-2.36).

CONCLUSIONS

In this population-based study of patients with ATC, nonwhite patients were found to be less likely to receive treatment. Furthermore, nonwhite patients had poorer overall survival, and patients living in areas of high poverty had both worse overall and disease-specific survival. Racial/ethnic and socioeconomic disparities appear to exist in the treatment and survival of patients with ATC. Cancer 2018;124:1780-90. © 2018 American Cancer Society.

摘要

背景

间变性甲状腺癌(ATC)是甲状腺癌中最罕见的类型,总生存率最低。据作者所知,社会经济地位和种族/民族的影响尚未描述。

方法

检查了 1998 年 1 月 1 日至 2011 年 12 月 31 日期间在监测、流行病学和最终结果(SEER)计划登记处诊断为首次原发性恶性 ATC 的 719 名患者的数据。根据种族/民族检查甲状腺切除术、放疗和淋巴结检查的差异。还根据种族/民族检查了生存情况。

结果

近 70%的患者为非西班牙裔白人,55.4%的患者接受了治疗。肿瘤大小(P=0.13)、淋巴结受累(P=0.60)和居住在高贫困社区(P=0.08)与种族/民族无关。非白人患者更有可能不接受治疗(调整后的优势比,0.29;95%置信区间[95%CI],0.16-0.54)。当调整放疗的接受情况时,非白人患者的总死亡风险更高(调整后的危害比[aHR],1.24;95%CI,1.01-1.54),尽管疾病特异性死亡(aHR,1.14;95%CI,0.92-1.42)没有增加。居住在高贫困地区的患者总体生存率较低(aHR,1.54;95%CI,1.09-2.18)和疾病特异性生存率(aHR,1.68;95%CI,1.19-2.36)。

结论

在这项基于人群的 ATC 患者研究中,发现非白人患者接受治疗的可能性较低。此外,非白人患者的总体生存率较差,居住在高贫困地区的患者总体生存率和疾病特异性生存率均较差。在 ATC 患者的治疗和生存方面似乎存在种族/民族和社会经济差异。癌症 2018;124:1780-90。©2018 美国癌症协会。

相似文献

1
Treatment and survival vary by race/ethnicity in patients with anaplastic thyroid cancer.在间变性甲状腺癌患者中,治疗方法和生存率因种族/民族而异。
Cancer. 2018 Apr 15;124(8):1780-1790. doi: 10.1002/cncr.31252. Epub 2018 Feb 6.
2
Association of Socioeconomic Status and Race/Ethnicity With Treatment and Survival in Patients With Medullary Thyroid Cancer.社会经济地位和种族/民族与甲状腺髓样癌患者治疗和生存的关系。
JAMA Otolaryngol Head Neck Surg. 2016 Aug 1;142(8):763-71. doi: 10.1001/jamaoto.2016.1051.
3
Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma.早期肝细胞癌患者在获得医疗服务和生存方面的种族/族裔差异。
Arch Surg. 2010 Dec;145(12):1158-63. doi: 10.1001/archsurg.2010.272.
4
Surgery combined with adjuvant radiation and chemotherapy prolonged overall survival in stage IVC anaplastic thyroid cancer: a SEER-based analysis.手术联合辅助放化疗延长 IVC 期间变性甲状腺癌的总生存期:基于 SEER 的分析。
Endocrine. 2024 Jul;85(1):250-257. doi: 10.1007/s12020-023-03662-7. Epub 2024 Jan 6.
5
Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer.大系列侵袭性甲状腺癌患者多模态治疗的结果。
Cancer. 2020 Jan 15;126(2):444-452. doi: 10.1002/cncr.32548. Epub 2019 Oct 8.
6
Development and validation of a nomogram to predict overall survival in patients with redefined anaplastic thyroid carcinoma based on the SEER database.基于 SEER 数据库构建并验证预测重新定义的间变性甲状腺癌患者总生存的列线图。
Int J Clin Oncol. 2024 Jun;29(6):744-754. doi: 10.1007/s10147-024-02495-2. Epub 2024 Apr 7.
7
Trends in Mortality for Anaplastic Thyroid Cancer: Have We Made Progress?甲状腺未分化癌死亡率趋势:我们有进展吗?
J Surg Res. 2024 Oct;302:476-483. doi: 10.1016/j.jss.2024.07.075. Epub 2024 Aug 20.
8
Treatment strategies and predicting lymph node metastasis in elderly patients with papillary thyroid microcarcinoma.老年甲状腺微小乳头状癌患者的治疗策略及淋巴结转移预测
Medicine (Baltimore). 2021 May 7;100(18):e25811. doi: 10.1097/MD.0000000000025811.
9
Disparities in Presentation, Treatment, and Survival in Anaplastic Thyroid Cancer.间变性甲状腺癌的临床表现、治疗和生存差异。
Ann Surg Oncol. 2023 Oct;30(11):6788-6798. doi: 10.1245/s10434-023-13945-y. Epub 2023 Jul 20.
10
Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma.间变性和低分化甲状腺癌的临床病理特征变化及生存结局。
Thyroid. 2016 Mar;26(3):404-13. doi: 10.1089/thy.2015.0316. Epub 2015 Dec 14.

引用本文的文献

1
Disparities in Thyroid Cancer Mortality Across Racial and Ethnic Groups: Assessing the Impact of Socioeconomic, Clinicopathologic, and Treatment Variations.不同种族和族裔群体甲状腺癌死亡率的差异:评估社会经济、临床病理和治疗差异的影响。
Ann Surg Oncol. 2025 Feb;32(2):1158-1175. doi: 10.1245/s10434-024-16569-y. Epub 2024 Nov 29.
2
Surgery combined with adjuvant radiation and chemotherapy prolonged overall survival in stage IVC anaplastic thyroid cancer: a SEER-based analysis.手术联合辅助放化疗延长 IVC 期间变性甲状腺癌的总生存期:基于 SEER 的分析。
Endocrine. 2024 Jul;85(1):250-257. doi: 10.1007/s12020-023-03662-7. Epub 2024 Jan 6.
3
Update on current diagnosis and management of anaplastic thyroid carcinoma.
间变性甲状腺癌的当前诊断与管理进展
World J Clin Oncol. 2023 Dec 24;14(12):570-583. doi: 10.5306/wjco.v14.i12.570.
4
Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.甲状腺间变癌治疗进展:将危及生命的疾病转化为可治疗的疾病。
Rev Endocr Metab Disord. 2024 Feb;25(1):123-147. doi: 10.1007/s11154-023-09833-1. Epub 2023 Aug 31.
5
Racial and Ethnic Disparities in the Diagnosis and Treatment of Thyroid Disease.种族和民族在甲状腺疾病的诊断和治疗中的差异。
J Clin Endocrinol Metab. 2024 Mar 15;109(4):e1336-e1344. doi: 10.1210/clinem/dgad519.
6
Disparities in Presentation, Treatment, and Survival in Anaplastic Thyroid Cancer.间变性甲状腺癌的临床表现、治疗和生存差异。
Ann Surg Oncol. 2023 Oct;30(11):6788-6798. doi: 10.1245/s10434-023-13945-y. Epub 2023 Jul 20.
7
Comparison of the cox regression to machine learning in predicting the survival of anaplastic thyroid carcinoma.比较 Cox 回归和机器学习在预测间变性甲状腺癌生存中的应用。
BMC Endocr Disord. 2023 Jun 5;23(1):129. doi: 10.1186/s12902-023-01368-5.
8
Socioeconomic deprivation and survival outcomes in primary central nervous system lymphomas.原发性中枢神经系统淋巴瘤的社会经济剥夺与生存结果
Front Oncol. 2022 Aug 26;12:929585. doi: 10.3389/fonc.2022.929585. eCollection 2022.
9
Disparities in Thyroid Care.甲状腺护理中的差异。
Endocrinol Metab Clin North Am. 2022 Jun;51(2):229-241. doi: 10.1016/j.ecl.2021.11.017. Epub 2022 May 4.
10
Radiotherapy Plus Chemotherapy Leads to Prolonged Survival in Patients With Anaplastic Thyroid Cancer Compared With Radiotherapy Alone Regardless of Surgical Resection and Distant Metastasis: A Retrospective Population Study.放化疗联合治疗可显著延长未手术切除及远处转移的间变性甲状腺癌患者的生存期,优于单纯放疗:一项回顾性人群研究。
Front Endocrinol (Lausanne). 2021 Nov 1;12:748023. doi: 10.3389/fendo.2021.748023. eCollection 2021.